These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 17690487

  • 1. Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients.
    Akinci B, Comlekci A, Yener S, Demir T, Ozcan MA, Bayraktar F, Yesil S.
    Endocr J; 2007 Aug; 54(4):593-9. PubMed ID: 17690487
    [Abstract] [Full Text] [Related]

  • 2. Effect of levothyroxine suppression therapy on plasma thrombin activatable fibrinolysis inhibitor antigen levels in benign thyroid nodules.
    Akinci B, Demir T, Comlekci A, Yener S, Ozcan MA, Karaoglu O, Yuksel F, Secil M, Yesil S.
    Med Princ Pract; 2011 Aug; 20(1):23-8. PubMed ID: 21160209
    [Abstract] [Full Text] [Related]

  • 3. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
    Ermantas N, Guldiken S, Demir M, Tugrul A.
    Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
    [Abstract] [Full Text] [Related]

  • 4. Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis.
    Yener S, Akarsu M, Demir T, Akinci B, Sagol O, Bayraktar F, Ozcan MA, Tankurt E, Yesil S.
    J Endocrinol Invest; 2007 Nov; 30(10):810-9. PubMed ID: 18075282
    [Abstract] [Full Text] [Related]

  • 5. Elevated thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels in overt and subclinical hypothyroid patients were reduced by levothyroxine replacement.
    Akinci B, Comlekci A, Ali Ozcan M, Demir T, Yener S, Demirkan F, Yuksel F, Yesil S.
    Endocr J; 2007 Feb; 54(1):45-52. PubMed ID: 17090955
    [Abstract] [Full Text] [Related]

  • 6. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.
    Erem C, Kocak M, Nuhoglu I, Yilmaz M, Ucuncu O.
    Eur J Endocrinol; 2009 May; 160(5):863-8. PubMed ID: 19233920
    [Abstract] [Full Text] [Related]

  • 7. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.
    Erem C, Nuhoglu I, Yilmaz M, Kocak M, Demirel A, Ucuncu O, Onder Ersoz H.
    J Endocrinol Invest; 2009 Feb; 32(2):169-74. PubMed ID: 19411818
    [Abstract] [Full Text] [Related]

  • 8. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1.
    Meltzer ME, Lisman T, de Groot PG, Meijers JC, le Cessie S, Doggen CJ, Rosendaal FR.
    Blood; 2010 Jul 08; 116(1):113-21. PubMed ID: 20385790
    [Abstract] [Full Text] [Related]

  • 9. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system.
    Zorio E, Castelló R, Falcó C, España F, Osa A, Almenar L, Aznar J, Estellés A.
    Br J Haematol; 2003 Sep 08; 122(6):958-65. PubMed ID: 12956767
    [Abstract] [Full Text] [Related]

  • 10. [Relationship between plasma levels of thrombin activatable fibrinolysis inhibitor, plasminogen activator inhibitor-1 and tissue-type plasminogen activator and deep venous thrombosis in patients with systemic lupus erythematosus].
    Liu YF, Hou N, Shi YJ, Li CX, Gao YJ, Liu LN.
    Zhonghua Yi Xue Za Zhi; 2023 Jun 06; 103(21):1638-1642. PubMed ID: 37248064
    [Abstract] [Full Text] [Related]

  • 11. Assessment of plasminogen activator inhibitor-1(PAI1) and thrombin activitable fibrinolysis inhibitor (TAFI) in Egyptian children with hemophilia A.
    Soliman M, Osman N, Hefnawy S, El Hawy MA.
    Pediatr Hematol Oncol; 2022 May 06; 39(4):318-328. PubMed ID: 34668834
    [Abstract] [Full Text] [Related]

  • 12. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hyperthyroidism.
    Erem C, Ucuncu O, Yilmaz M, Kocak M, Nuhoglu İ, Ersoz HO.
    Endocrine; 2009 Dec 06; 36(3):473-8. PubMed ID: 19859836
    [Abstract] [Full Text] [Related]

  • 13. Active PAI-1 as marker for venous thromboembolism: case-control study using a comprehensive panel of PAI-1 and TAFI assays.
    Bollen L, Peetermans M, Peeters M, Van Steen K, Hoylaerts MF, Declerck PJ, Verhamme P, Gils A.
    Thromb Res; 2014 Nov 06; 134(5):1097-102. PubMed ID: 25193405
    [Abstract] [Full Text] [Related]

  • 14. Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor.
    Aso Y, Wakabayashi S, Yamamoto R, Matsutomo R, Takebayashi K, Inukai T.
    Diabetes Care; 2005 Sep 06; 28(9):2211-6. PubMed ID: 16123492
    [Abstract] [Full Text] [Related]

  • 15. Fibrinolysis inhibitors in plaque stability: a morphological association of PAI-1 and TAFI in advanced carotid plaque.
    Jönsson Rylander AC, Lindgren A, Deinum J, Bergström GM, Böttcher G, Kalies I, Wåhlander K.
    J Thromb Haemost; 2017 Apr 06; 15(4):758-769. PubMed ID: 28135035
    [Abstract] [Full Text] [Related]

  • 16. Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation.
    Watanabe R, Wada H, Watanabe Y, Sakakura M, Nakasaki T, Mori Y, Nishikawa M, Gabazza EC, Nobori T, Shiku H.
    Thromb Res; 2001 Oct 01; 104(1):1-6. PubMed ID: 11583733
    [Abstract] [Full Text] [Related]

  • 17. Fibrinolysis parameters in Sudanese women with severe preeclampsia.
    Elzein HO, Muddathir AR, Rida M, Rayis DA, Elhassan EM, Adam I.
    Hypertens Pregnancy; 2016 Nov 01; 35(4):559-564. PubMed ID: 27598010
    [Abstract] [Full Text] [Related]

  • 18. Gestational diabetes has no additional effect on plasma thrombin-activatable fibrinolysis inhibitor antigen levels beyond pregnancy.
    Akinci B, Demir T, Saygili S, Yener S, Alacacioglu I, Saygili F, Bayraktar F, Yesil S.
    Diabetes Res Clin Pract; 2008 Jul 01; 81(1):93-6. PubMed ID: 18406001
    [Abstract] [Full Text] [Related]

  • 19. Thrombin activatable fibrinolysis inhibitor (TAFI): a molecular link between coagulation and fibrinolysis.
    Miljić P, Heylen E, Willemse J, Djordjević V, Radojković D, Colović M, Elezović I, Hendriks D.
    Srp Arh Celok Lek; 2010 Jan 01; 138 Suppl 1():74-8. PubMed ID: 20229688
    [Abstract] [Full Text] [Related]

  • 20. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
    Erem C.
    Clin Endocrinol (Oxf); 2006 Mar 01; 64(3):323-9. PubMed ID: 16487444
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.